“Dermatology has been treating hair loss with a drug borrowed from cardiology, in a formulation never intended for our patients, at doses we arrived at informally. VDPHL01 is the first oral minoxidil formulation developed specifically for pattern hair loss, and now the first to generate positive Phase 3 results of efficacy and safety.”
Enhanced made public Wednesday the drug-use rates of 36 of the athletes scheduled to compete, announcing that its clinical study is listed on Clinicaltrials.gov. Two of the 36 included in the study and two of the six not included in the study are competing without PEDs, meaning 90.5% of the athletes are juiced.
There's lots of uncertainty around how the Senate will find the bandwidth to confirm another FDA commissioner while it considers President Trump's nominees for Centers for Disease Control and Prevention director and surgeon general. The FDA itself is also facing other key internal vacancies, including for directors of the centers overseeing drugs and biologics. And there are questions about whether a successor will continue efforts to streamline clinical trials and other regulatory actions.
Currently there is no effective vaccine against Hanta viruses, leaving large populations in Southeast Asia, Africa and South America vulnerable to diseases that are originated and transmitted by rodents. Our team has developed a new antigen against Hantaan disease, from the Hanta virus group. This is a completely new vaccine that has now been tested in the laboratory and in animal models, indicating excellent immune response. While more work needs to be done to bring this vaccine to public - clinical trials and approvals - this is a very promising development of a completely new and needed vaccine.
It's not for us. It's for my sister's children and their children, so that they won't have the same 'nothing' to choose from. Ward is a member of the Dominantly Inherited Alzheimer Network (DIAN), a group of more than 200 families in 18 countries who carry gene mutations that cause symptoms to appear in middle age, or even earlier.
Novo Nordisk plans to deploy advanced artificial intelligence capabilities to analyze complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient.
The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care.
One theory is that by slowing the rate of biological ageing, it may be possible to prevent or mitigate age-related illness, meaning people have more years of good health. A study carried out by researchers in the US and including funding from the confectionery manufacturer Mars suggests a daily multivitamin could help slow some markers of biological ageing – although what that means in terms of health remains unclear.
For more than 60 years, contraception has been almost exclusively a women's responsibility. Today, women have more than 14 modern contraceptive options, while men have just two: condoms and vasectomies. That imbalance has pushed women to shoulder physical side effects, financial burden, medical risks, and the career impact of family planning-costs that have been accepted as the "status quo" for far too long.
When Lisa Dutton was declared free of breast cancer in 2017, she took a moment to celebrate with family and friends, even though she knew her cancer journey might not be over. As many as one-third of people whose breast tumours are cleared see the disease come back, sometimes decades later. Many other cancers are known to recur in the years following an initial treatment, some at much higher rates.
However, it is regrettable that an organisation such as the World Health Organization appears willing to promote the incorporation of traditional and other medicines into mainstream practice by leaning heavily on emotive language heritage, tradition, and the sharing of local resources rather than on clinical evidence. Then it appears to contradict itself by saying that it doesn't support it if there isn't robust and reliable evidence.
London's position as Europe's leading clinical research hub generates profound impacts extending far beyond laboratory walls and hospital wards. Hundreds of London trials running simultaneously create a sophisticated ecosystem connecting pharmaceutical companies, research institutions, healthcare providers, and most importantly, thousands of patients seeking access to innovative treatments whilst contributing to medical advancement. This ecosystem delivers tangible economic value whilst simultaneously addressing patient needs that conventional healthcare often cannot meet.
The biotech company, which is headquartered in Milpitas, turned in a Chapter 7 filing, meaning that it seeks liquidation, rather than reorganization. The document is so sparse that it prompted a request from the court's deputy clerk for more information. But it depicts a company in dire straits: ASC Therapeutics estimates that it has between $100,000 and $500,000 in assets and between $10 million and $50 million in liabilities.
Cuba is battling a wave of mosquito-borne illnesses, with the country's top epidemiologist warning that nearly one-third of the population has been impacted, with large numbers of workers taken ill. On Thursday, fumigators armed with fogging machines probed alleys and crowded buildings in parts of the capital Havana, among the hardest hit by mosquito-borne viruses including dengue and chikungunya, authorities said.
The groundbreaking clinical trial, described on 31 October in the American Journal of Human Genetics, will deploy an offshoot of the CRISPR-Cas9 gene-editing technique called base editing, which allows scientists to make precise, single-letter changes to DNA sequences. The study is expected to begin next year, after its organizers spent months negotiating with US regulators over ways to simplify the convoluted path a gene-editing therapy normally has to take before it can enter trials.
The announcement of a positive result from a major clinical trial is an incredibly exciting moment in the world of medicine. It's a validation of years of painstaking research, a potential new tool for doctors, and, most importantly, a powerful new source of hope for patients and their families. As a physician or a researcher, the desire to share this exciting news with the public is a natural one.
